labcorp holdings - LH
LH
Close Chg Chg %
240.05 -0.45 -0.19%
Closed Market
239.60
-0.45 (0.19%)
Volume: 436.36K
Last Updated:
Nov 22, 2024, 3:59 PM EDT
Company Overview: labcorp holdings - LH
LH Key Data
Open $240.04 | Day Range 238.82 - 240.97 |
52 Week Range 191.97 - 247.98 | Market Cap $20.09B |
Shares Outstanding 83.64M | Public Float 83.35M |
Beta 1.05 | Rev. Per Employee N/A |
P/E Ratio 46.50 | EPS $5.20 |
Yield 119.92% | Dividend $0.72 |
EX-DIVIDEND DATE Nov 26, 2024 | SHORT INTEREST N/A |
AVERAGE VOLUME 760.40K |
LH Performance
1 Week | 2.11% | ||
1 Month | 5.05% | ||
3 Months | 4.02% | ||
1 Year | 12.90% | ||
5 Years | 66.42% |
LH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
20
Full Ratings ➔
About labcorp holdings - LH
Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
LH At a Glance
Labcorp Holdings, Inc.
358 South Main Street
Burlington, North Carolina 27215-5837
Phone | 1-336-229-1127 | Revenue | 12.16B | |
Industry | Medical/Nursing Services | Net Income | 418.00M | |
Sector | Health Services | Employees | 67,000 | |
Fiscal Year-end | 12 / 2024 | |||
View SEC Filings |
LH Valuation
P/E Current | 46.051 |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | 47.633 |
Price to Sales Ratio | 1.637 |
Price to Book Ratio | 2.422 |
Price to Cash Flow Ratio | 14.996 |
Enterprise Value to EBITDA | 14.868 |
Enterprise Value to Sales | 2.084 |
Total Debt to Enterprise Value | 0.235 |
LH Efficiency
Revenue/Employee | 181,516.418 |
Income Per Employee | 6,238.806 |
Receivables Turnover | 5.795 |
Total Asset Turnover | 0.66 |
LH Liquidity
Current Ratio | 1.167 |
Quick Ratio | 1.02 |
Cash Ratio | 0.166 |
LH Profitability
Gross Margin | 25.861 |
Operating Margin | 9.24 |
Pretax Margin | 4.678 |
Net Margin | 3.437 |
Return on Assets | 2.056 |
Return on Equity | 4.22 |
Return on Total Capital | 2.742 |
Return on Invested Capital | 2.656 |
LH Capital Structure
Total Debt to Total Equity | 75.609 |
Total Debt to Total Capital | 43.055 |
Total Debt to Total Assets | 35.60 |
Long-Term Debt to Equity | 60.726 |
Long-Term Debt to Total Capital | 34.58 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Labcorp Holdings - LH
Collapse All in section
All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
---|---|---|---|---|---|
Sales/Revenue
| 13.98B | 16.12B | 14.88B | 12.16B | |
Sales Growth
| +20.98% | +15.33% | -7.72% | -18.25% | |
Cost of Goods Sold (COGS) incl D&A
| 9.30B | 10.87B | 10.75B | 9.02B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 825.00M | 940.00M | 828.30M | 580.90M | |
Depreciation
| 549.60M | 570.40M | 569.00M | 361.10M | |
Amortization of Intangibles
| 275.40M | 369.60M | 259.30M | 219.80M | |
COGS Growth
| +8.84% | +16.83% | -1.06% | -16.13% | |
Gross Income
| 4.68B | 5.25B | 4.13B | 3.15B | |
Gross Income Growth
| +55.43% | +12.34% | -21.48% | -23.77% | |
Gross Profit Margin
| +33.46% | +32.60% | +27.73% | +25.86% |
2020 | 2021 | 2022 | 2023 | 5-year trend | |
---|---|---|---|---|---|
SG&A Expense
| 1.71B | 1.89B | 2.00B | 2.02B | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 1.71B | 1.89B | 2.00B | 2.02B | |
SGA Growth
| +8.82% | +10.91% | +5.41% | +1.24% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 524.20M | 101.10M | 355.30M | 398.10M | |
EBIT after Unusual Expense
| 2.45B | 3.26B | 1.77B | 725.60M | |
Non Operating Income/Expense
| (18.90M) | 79.20M | (11.00M) | 42.90M | |
Non-Operating Interest Income
| 10.30M | 10.20M | 8.90M | 28.80M | |
Equity in Earnings of Affiliates
| 2.90M | 26.50M | 5.40M | (1.40M) | |
Interest Expense
| 207.40M | 212.10M | 180.30M | 199.60M | |
Interest Expense Growth
| -13.83% | +2.27% | -14.99% | +10.70% | |
Gross Interest Expense
| 207.40M | 212.10M | 180.30M | 199.60M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 2.22B | 3.13B | 1.58B | 568.90M | |
Pretax Income Growth
| +100.84% | +40.89% | -49.38% | -64.05% | |
Pretax Margin
| +15.88% | +19.39% | +10.64% | +4.68% | |
Income Tax
| 662.10M | 747.10M | 302.00M | 188.50M | |
Income Tax - Current - Domestic
| 628.10M | 717.40M | 229.50M | 222.00M | |
Income Tax - Current - Foreign
| 81.00M | 107.70M | 65.30M | 44.60M | |
Income Tax - Deferred - Domestic
| (34.80M) | (78.30M) | 2.40M | (94.70M) | |
Income Tax - Deferred - Foreign
| (12.20M) | 300.00K | 4.80M | 16.60M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 2.90M | 26.50M | 5.40M | (1.40M) | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 1.56B | 2.38B | 1.28B | 380.40M | |
Minority Interest Expense
| 900.00K | 2.20M | 1.50M | 1.20M | |
Net Income
| 1.56B | 2.38B | 1.28B | 379.20M | |
Net Income Growth
| +88.89% | +52.77% | -46.20% | -70.35% | |
Net Margin Growth
| +11.13% | +14.75% | +8.60% | +3.12% | |
Extraordinaries & Discontinued Operations
| - | - | - | 38.80M | - |
Discontinued Operations
| - | - | - | 38.80M | - |
Net Income After Extraordinaries
| 1.56B | 2.38B | 1.28B | 418.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 1.56B | 2.38B | 1.28B | 418.00M | |
EPS (Basic)
| 15.9928 | 24.5843 | 14.0406 | 4.7991 | |
EPS (Basic) Growth
| +90.06% | +53.72% | -42.89% | -65.82% | |
Basic Shares Outstanding
| 97.30M | 96.70M | 91.10M | 87.10M | |
EPS (Diluted)
| 15.8786 | 24.3826 | 13.964 | 4.7717 | |
EPS (Diluted) Growth
| +90.05% | +53.56% | -42.73% | -65.83% | |
Diluted Shares Outstanding
| 98.00M | 97.50M | 91.60M | 87.60M | |
EBITDA
| 3.79B | 4.30B | 2.96B | 1.70B | |
EBITDA Growth
| +71.61% | +13.33% | -31.23% | -42.36% | |
EBITDA Margin
| +27.15% | +26.68% | +19.88% | +14.02% |
Snapshot
Average Recommendation | OVERWEIGHT | Average Target Price | 263.688 | |
Number of Ratings | 20 | Current Quarters Estimate | 3.40 | |
FY Report Date | 12 / 2024 | Current Year's Estimate | 14.528 | |
Last Quarter’s Earnings | 3.50 | Median PE on CY Estimate | N/A | |
Year Ago Earnings | 13.56 | Next Fiscal Year Estimate | 16.01 | |
Median PE on Next FY Estimate | N/A |
Earnings Per Share
This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
---|---|---|---|---|
# of Estimates | 16 | 13 | 18 | 18 |
Mean Estimate | 3.40 | 3.87 | 14.53 | 16.01 |
High Estimates | 3.52 | 4.06 | 14.65 | 16.90 |
Low Estimate | 3.24 | 3.59 | 14.37 | 15.75 |
Coefficient of Variance | 1.95 | 3.64 | 0.44 | 1.65 |
Analysts Recommendations
Current | 1 Month Ago | 3 Months Ago | |
---|---|---|---|
BUY | 12 | 12 | 10 |
OVERWEIGHT | 2 | 2 | 2 |
HOLD | 6 | 7 | 6 |
UNDERWEIGHT | 0 | 0 | 0 |
SELL | 0 | 0 | 0 |
MEAN | Overweight | Overweight | Overweight |
SEC Filings for Labcorp Holdings - LH
Filing Date | Type | Category | Amended |
---|---|---|---|
No results |
Insider Actions for Labcorp Holdings - LH
Date | Name | Shares | Transaction | Value |
---|---|---|---|---|
May 16, 2024 | Sandra Danett van der Vaart EVP, Chief Legal Officer | 5,837 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $210.83 per share | 1,230,614.71 |
May 16, 2024 | Sandra Danett van der Vaart EVP, Chief Legal Officer | 5,637 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $210.84 per share | 1,188,505.08 |
May 3, 2024 | Kerrii B. Anderson Director | 15,972 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $204.14 per share | 3,260,524.08 |
May 3, 2024 | Glenn Andrew Eisenberg Chief Financial Officer, EVP | 46,289 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $201.37 per share | 9,321,215.93 |
May 3, 2024 | Glenn Andrew Eisenberg Chief Financial Officer, EVP | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
May 3, 2024 | Kerrii B. Anderson Director | 15,722 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $200.1 per share | 3,145,972.20 |
May 3, 2024 | Glenn Andrew Eisenberg Chief Financial Officer, EVP | 50,785 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
May 2, 2024 | Peter J. Wilkinson SVP, Chief Accounting Officer | 2,087 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $204.33 per share | 426,436.71 |
Mar 11, 2024 | Mark S. Schroeder EVP, Pres Diagnostics & COO | 5,036 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $218.45 per share | 1,100,114.20 |
Mar 11, 2024 | Mark S. Schroeder EVP, Pres Diagnostics & COO | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Mar 11, 2024 | Amy B. Summy EVP, Chief Marketing Officer | 3,859 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $218.45 per share | 842,998.55 |
Mar 11, 2024 | Mark S. Schroeder EVP, Pres Diagnostics & COO | 10,084 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $117.09 per share | 1,180,735.56 |
Feb 23, 2024 | Jonathan DiVincenzo EVP, Pres, Central Labs & Intl | 3,401 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $215.49 per share | 732,881.49 |
Feb 23, 2024 | Glenn Andrew Eisenberg Chief Financial Officer, EVP | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Feb 23, 2024 | Glenn Andrew Eisenberg Chief Financial Officer, EVP | 23,595 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $217.98 per share | 5,143,238.10 |
Feb 23, 2024 | Glenn Andrew Eisenberg Chief Financial Officer, EVP | 25,148 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $217.52 per share | 5,470,192.96 |
Feb 14, 2024 | Adam H. Schechter President & CEO; Director | 54,225 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Feb 14, 2024 | Adam H. Schechter President & CEO; Director | 95,277 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
Feb 14, 2024 | Adam H. Schechter President & CEO; Director | 52,994 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $227.45 per share | 12,053,485.30 |
Feb 14, 2024 | Lance V. Berberian EVP, CIO & CTO | 23,616 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $227.45 per share | 5,371,459.20 |